Legal analysis: First, the total abolition of the drug markup. Public hospitals of all levels and types by the end of September to cancel all drug markups, in addition to traditional Chinese medicine tablets in addition to the implementation of zero-difference rate sales of medicines. The abolition of drug markups reduce the reasonable income, mainly by adjusting the price of medical services to compensate, and do a good job with the financial input policy, promote the abolition of the "medicine for medicine", the establishment of a new compensation mechanism in line with the characteristics of the medical industry.
The second is to optimize the price structure of medical services. In accordance with the requirements of "controlling the total amount, making space, adjusting the structure, ensuring convergence", dynamic adjustment of medical service prices, and gradually rationalize the price relationship. The focus is to increase the price of diagnosis and treatment, surgery, rehabilitation, nursing, Chinese medicine and other items reflecting the value of the technical services of medical personnel, and reduce the price of large-scale medical equipment inspection and treatment and testing.
Third, synchronize and support related reforms. Strengthen and medicine, health insurance, medical and other reform policies synergistic linkage, synchronized promotion. In particular, to do a good job of articulation with the health insurance policy, adjusted medical service charges to be included in the scope of payment of health insurance. It is necessary to make room for adjusting the price of medical services by standardizing diagnostic and treatment behavior and reducing the cost of drugs and consumables. To promote hierarchical diagnosis and treatment, modern hospital management system and strengthen the comprehensive supervision, forming a synergistic effect of reform.
Fourth is to balance the interests of the relevant parties. Correctly handle the relationship between medical institutions, health insurance funds, patients and other parties, and take into account the interests of all parties to ensure that the benign operation of medical institutions, health insurance funds affordable, the overall burden on the public does not increase. To establish a bottom-line thinking, attach great importance to protecting the interests of special disease groups, low-income groups, especially poor families, to protect the basic medical needs of these groups.
Legal basis: "Chinese People's **** and State Social Insurance Law" Article 2 The State establishes a social insurance system of basic old-age insurance, basic medical insurance, industrial injury insurance, unemployment insurance, maternity insurance and other social insurance systems, and guarantees the right of citizens to obtain material assistance from the State and society in accordance with the law in the event of old age, illness, industrial injury, unemployment and maternity.
The Law of the People's Republic of China on the Administration of Medicines
Article 42 To engage in the production of medicines, the following conditions shall be met:
(1) the existence of pharmacy technicians, engineers and corresponding skilled workers who have been accredited in accordance with the law;
(2) the existence of plants, facilities and sanitary environments that are compatible with the production of medicines;
(C) the quality of the drugs produced by the quality management and quality inspection of institutions, personnel and the necessary equipment;
(D) have to ensure that the quality of drugs and regulations, and in line with the State Council drug supervision and management department in accordance with the requirements of this Law formulated by the pharmaceutical production and quality management standards.
Article 43 engaged in pharmaceutical production activities, shall comply with the pharmaceutical production quality management standards, establish and improve the pharmaceutical production quality management system, to ensure that the whole process of pharmaceutical production continues to meet the statutory requirements.
The legal representative of the drug manufacturer, the main person in charge of the enterprise's drug production activities are fully responsible.
Article 44 Drugs shall be produced in accordance with national drug standards and the production process approved by the drug regulatory authorities. Production and inspection records shall be complete and accurate, and shall not be fabricated.
Chinese medicinal tablets shall be concocted in accordance with national drug standards; national drug standards do not provide, shall be in accordance with the provincial, autonomous regions, municipalities directly under the Central People's Government of the People's Government of the drug supervision and management department of the concoction specification concoction. Provinces, autonomous regions, municipalities directly under the Central People's Government of the drug supervision and management department to formulate the concoction specification should be reported to the State Council drug supervision and management department for the record. Does not meet the national drug standards or not in accordance with the provincial, autonomous regions, municipalities directly under the Central People's Government of the People's Government of the drug supervision and management department of the formulation of concoction specifications of the concoction, shall not be shipped, sold.